[1] 左来刚,王家璧.肿胀性红斑狼疮.中华皮肤科杂志,2002,35:70-72.
[2] Stoll T, Stucki G, Malik J, et al. Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus. J Rheumatol, 1997, 24:309-313.
[3] Rapp CA, Berner B, Muller GA, et al.Long-term analysis of clinical disease activity and chronic organ damage in patients with systemic lupus erythematosus. Z Rheumatol, 2002, 61:521-531.
[4] Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum, 1992, 35:630-640.
[5] Gladman DD, Urowitz MB, Kagal A, et al.Accurately describing changes in disease activity in Systemic Lupus Erythematosus. J Rheumatol, 2000, 27:377-379.
[6] Smolen JS. Therapy of systemic lupus erythematosus:a look into the future. Arthritis Res, 2002, 4 Suppl 3:S25-30.
[7] [No authors listed] . Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines.Arthritis Rheum, 1999, 42:17g5-1796.
[8] 李学平,冒长峙,满孝勇,等.系统性红斑狼疮的治疗进展.中华皮肤科杂志,2001,34:157-158.
[9] Badsha H, Edwards CJ. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum,2003, 32:370-377.
[10] Ortmann RA, Klippel JH. Update on cyclophosphamide for systemic lupus erythematosus. Rheum Dis Clin North Am, 2000,26:363-375.
[11] McMurray RW. Nonstandard and adjunctive medical therapies for systemic lupus erythematosus. Arthritis Rheum, 2001, 45:86-100.
[12] 弓娟琴,靳培英.达那唑治疗某些皮肤病的进展.中华皮肤科杂志,2003,36:609-611.
[13] 郝进,郝飞.系统性红斑狼疮生物制剂治疗的研究进展.国外医学皮肤性病学分册,2002,28:208-211.
[14] Guma M, Olive A, Roca J, et al. Association of systemic lupus erythematosus and hypermobility. Ann Rheun Dis, 2002, 61:1024-1026. |
